Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (161-170 of 186) with videos related to

Pageof 19
Sort By:
NPJ Breast Cancer|January 5, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
The Oncologist|January 21, 2015
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysisMiguel Martín, Noelia Martínez, Manuel Ramos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of RelapseAleix Prat, Ana Lluch, Arran K Turnbull, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
NPJ Breast Cancer|April 29, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2018
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment SubstudyCristina Cruz, Alba Llop-Guevara, Judy E Garber, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 19, 2022
Physicians' attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey studyBertha Alejandra Martinez-Cannon, Enrique Soto-Perez-de-Celis, Aura Erazo Valle-Solis, et al.
Oncotarget|April 21, 2017
Critically short telomeres and toxicity of chemotherapy in early breast cancerMiguel Quintela-Fandino, Nora Soberon, Ana Lluch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2016
<sup>18</sup>F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized TrialMiguel Quintela-Fandino, Ana Lluch, Luis Manso, et al.
Pageof 19

Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
NPJ Breast Cancer|January 5, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
The Oncologist|January 21, 2015
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysisMiguel Martín, Noelia Martínez, Manuel Ramos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of RelapseAleix Prat, Ana Lluch, Arran K Turnbull, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
NPJ Breast Cancer|April 29, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2018
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment SubstudyCristina Cruz, Alba Llop-Guevara, Judy E Garber, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 19, 2022
Physicians' attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey studyBertha Alejandra Martinez-Cannon, Enrique Soto-Perez-de-Celis, Aura Erazo Valle-Solis, et al.
Oncotarget|April 21, 2017
Critically short telomeres and toxicity of chemotherapy in early breast cancerMiguel Quintela-Fandino, Nora Soberon, Ana Lluch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2016
<sup>18</sup>F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized TrialMiguel Quintela-Fandino, Ana Lluch, Luis Manso, et al.
Pageof 19